ContraVir Pharmaceutical's CEO James Sapirstein Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - May 28, 2015) - Nobody understands the ins and outs of the antivirals better than the CEO of ContraVir Pharmaceuticals (NASDAQ: CTRV), and James Sapirstein unfolds the backstory behind the creation of his newest venture in this interview with The Life Sciences Report. Millions of patients around the globe await the unveiling of the company's emerging pipeline products targeting the viruses that cause shingles and hepatitis B -- products that also promise opportunity to biotech investors.

The Life Sciences Report: Let's start with ContraVir Pharmaceuticals Inc.'s lead product. What is FV-100?

James Sapirstein: FV-100 is an antiviral compound that is specific for a virus called herpes zoster, also known as varicella zoster or the chickenpox virus. When a kid gets chickenpox, a rash pops up, but the pox is not painful. When adults get it the virus is called shingles, and it is very painful. The nerve pain is called postherpetic neuralgia (PHN). Other antivirals used to treat shingles work against several types of herpes virus, including herpes simplex 1 and herpes simplex 2, but they don't have much specificity for herpes zoster or pain.

Our product, FV-100, does not work against the other herpes viruses. It is dialed in specifically for herpes zoster, and it targets the dorsal root ganglion of the nerve, which the virus inhabits. It helps stop replication of the virus in the dorsal root ganglion. One of the nice things about this product is that...

Continue reading this interview with James Sapirstein: ContraVir Pharmaceuticals Brandishes a New Weapon in Biotech's Antiviral Wars

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE:

ContraVir Pharmaceuticals paid The Life Sciences Report to conduct, produce and distribute the interview. James Sapirstein had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of James Sapirstein and not of The Life Sciences Report or its officers.